Live, Attenuated Vaccines Against Pneumoviruses
- Detailed Technology Description
- Mutation of the RSV NS1/2 proteins to attenuate the virus and boost immunogenicity
- Countries
- Not Available
- Application No.
- None
- *Abstract
-
Respiratory syncytial virus (RSV) is the most frequent cause of lower respiratory disease and hospitalization in infants, but there is currently no vaccine or effective therapy available to prevent or treat RSV disease. Researchers at Nationwide Children's Hospital and The Ohio State University are working to develop a live, attenuated RSV vaccine to prevent infection in at risk populations. There are several technologies that have resulted from the RSV research program with more than one performing well in pre-clinical animal trials. Researchers are also working to develop a live, attenuated vaccine to protect against human metapneumovirus (hMPV). For example, a strategic mutation in one of the vaccine candidates has been shown to attenuate virus replication in cotton rats while retaining immunogenicity.
- *Inquiry
- Andrew CorrisThe Research Institute at Nationwide Children's HospitalOffice of Technology Commercialization700 Children's Drive Columbus OH 43205T: 614 355-1604 F: 614 722-2716Andrew.Corris@nationwidechildrens.org
- *IP Issue Date
- None
- *IP Type
- Other Patent
- Country/Region
- USA
